Irvine Scientific Receives FDA 510(k) Clearance for Their Newly Developed Continuous Single Culture™ - Complete Product, a Novel Solution Designed for Human Embryo Culture
Irvine Scientific , a global leader in Assisted Reproductive Technologies (ART) , announced that they have received 510(k) clearance for their Continuous Single Culture™ - Complete product (CSCM-C). The company will commence commercialization at IVF centers across the United States immediately. The product will be presented at the 68th Annual Meeting of the American Society for Reproductive Medicine in San Diego, California from October 20th -24th 2012.
CSCM-C is a complex solution which is pre-supplemented with Human Serum Albumin, intended to be used for fertilization and culture of embryos to D-3, or D-5/D-6 of development. CSCM-C is the first and only single-step culture medium used in an uninterrupted culture environment, without the need for medium renewal or dish change. Designed for laboratories who want to reduce stress on embryos while improving clinical results, the optimized formulation reduces embryo stress by eliminating the need to expose embryos to varying media environments, temperature and pH fluctuations. The new CSCM-C product improves blastocyst formation with a demonstrated increase in blastocyst utilization and fertilization rates.
“We are very pleased to be the first and only company at this time that offers a monoculture solution for both fertilization and extended embryo culture in an uninterrupted culture environment,” expresses Tim Mullane, COO. He adds that, “CSCM-C represents an important addition to a series of innovative products offered by Irvine Scientific that provide a simplified and efficient approach to achieving pregnancies in-vitro. But more importantly, provides a complete solution for laboratories that strive to reduce embryo stress while providing patients with a healthy baby.”
Irvine Scientific , a member of JX Holdings group, is a worldwide leader in the design, manufacture and distribution of medical devices, including Industrial Cell Culture , Cytogenetic, Assisted Reproductive Technology (ART) and Specialty Media products. Irvine Scientific is a large scale producer of advanced quality cell culture media for the industrial bioprocess, medical, and diagnostic markets. The company’s extensive experience in the design of culture media, compliance with ISO and FDA regulations for class II / III medical devices, industrial scale manufacturing capacity, provides its customers with unique capabilities and support. Irvine Scientific delivers products worldwide to biopharmaceutical industry, research and medical laboratory communities.
Irvine Scientific® and Continuous Single Culture™ are among the trademarks of Irvine Scientific Sales Company, Inc. and its affiliates in the United States, certain other countries and/or the EU.
For more information:
- Visit http://www.irvinesci.com
- Follow us on LinkedIn at http://www.linkedin.com/company/irvine-scientific?trk=tabs_biz_home
Contact:
Irvine Scientific
Fairy Zare
1-800-437-5706
1-949-261-7800
tmrequest@irvinesci.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
The Future of Connectivity Starts Here: Network X Returns to Paris October 14 - 1616.7.2025 09:00:00 CEST | Press release
Show Reconvenes at Paris Expo Porte de Versailles with Global Representation of Industry Leaders and Telco Experts Network X 2025 - the only event that brings the fixed and mobile markets together - returns to Paris Expo Porte de Versailles October 14 - 16. Built for telecom's top players, this annual show drives business model innovation and monetisation of next-generation fixed, mobile, satellite and transport networks through AI and cloud. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250716595903/en/ Speaker on Headliners Stage at Network X 2024 New to Network X in 2025 are specialty events designed to deliver expert insights on trending topics including Data Center World and two Expo Stages for Fixed-Line and Mobile. More than 5,500 telco network infrastructure professionals will gather alongside 1,500 telcos to learn from six program tracks highlighting the latest advancements in Fibre, Wi-Fi Networks and Services, IP
Skechers AERO Series Opens New Chapter of Technical Running Innovation16.7.2025 09:00:00 CEST | Press release
New Collection Features an Evolution in Design that Cuts Through the Wind for That Aerodynamic Feel on Every Run Skechers Performance opens a new chapter of running innovation with the arrival of the Skechers AERO series. Named for the aerodynamic feel of the design, Skechers AERO represents the latest evolution of technical running shoes from the brand. The collection is engineered to deliver an exhilarating blend of speed, style and comfort to help runners cut through the wind and push beyond their personal bests while logging miles. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250716754749/en/ Introducing the Skechers AERO Series of technical running shoes: Skechers AERO Burst, Skechers AERO Spark, and Skechers AERO Tempo (L-R). “Recently launched in North America and Asia, the AERO Series leverages innovative technologies to elevate our signature comfort that’s now available to runners in Europe,” said Ben Stewart, Vic
4Moving Biotech Enrolls First Patient in Phase 2a Trial of 4P004, a Potential First-in-Class GLP-1 Therapy for Knee Osteoarthritis16.7.2025 07:00:00 CEST | Press release
- First patient enrolled in INFLAM MOTION, a global randomized Phase 2a trial including 129 knee osteoarthritis patients - 4P004 to be evaluated over 3 months for dual efficacy: symptom relief and synovial health improvement via contrast-enhanced MRI - Topline results expected in the second half of 2026 4Moving Biotech (4MB), a spin-off of 4P-Pharma dedicated to developing first-in-class treatments that modify the natural course of knee osteoarthritis (OA), today announced that the first patient has been enrolled in Phase 2a clinical trial, INFLAM MOTION. The study will evaluate 4P004, an intra-articular GLP-1 analog, as a potential first-in-class therapeutic candidate for knee osteoarthritis. INFLAM MOTION is a multicenter, randomized, double-blind, placebo-controlled Phase 2a trial planned to be conducted across Europe, the United States, and Canada. A total of 129 patients worldwide diagnosed with knee OA will be enrolled to evaluate, for the first time in humans, the efficacy of 4P
Belkin Achieves Qi2.2 Certification for Its Upcoming Products, Unlocking the Future of 25W Wireless Charging15.7.2025 19:06:00 CEST | Press release
With Qi2.2 certification, Belkin reinforces its commitment to quality, safety, and performance for the next generation of wireless charging Belkin, a leading consumer electronics brand for over 40 years, today announced it has received official Qi2.2 certification from the Wireless Power Consortium (WPC) for its upcoming products. As one of the first accessory brands to deliver Qi2.2-certified devices, Belkin is helping bring the next generation of wireless charging to market – enabling faster wireless charging speeds, broader compatibility, and improved performance for consumers. Belkin’s close partnership with the WPC since 2015 has been instrumental in bringing these advancements to consumers. As an early adopter and long-time contributor to WPC standards, Belkin was selected as one of a small group of trusted manufacturers to test and certify Qi2.2 products ahead of the broader industry rollout. All Belkin products undergo rigorous safety, quality, and performance testing. The comp
Cessna Grand Caravan EX to Feature New Executive Interior Options, Expanding Opportunities for Elevated Missions15.7.2025 18:05:00 CEST | Press release
The legendary Cessna Grand Caravan EX will now feature three new executive interior schemes for customers to select when designing their aircraft cabin. The Lunar, Obsidian and Saddle Sport interiors join the existing Canyon and Savanna schemes, providing a broader range of standard choices. The new interior options are available to customers starting this month and allow them to further tailor the interior of their aircraft based on their personal preference or mission. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250715021096/en/ Cessna Grand Caravan EX to feature new executive interior options, expanding opportunities for elevated missions (Photo Credit: Textron Aviation) The Cessna Grand Caravan EX is designed and manufactured by Textron Aviation Inc., a Textron Inc. (NYSE:TXT) company. Premium versions of each of the new interiors are also available, featuring quilted seat stitching and plush carpet, providing an elev
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom